Markers in the blood can predict how multiple sclerosis will develop and what drugs will be ­effective, a study found.

Recent developments in health include EU approval of Novo's Wegovy for obesity-related heart conditions, the US FDA's nod for ...

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

The latest health news covers the European Medicines Agency supporting Novo Nordisk’s drug for heart failure in obese ...

What's new at Jacksonville Public Library: "Colored Television" by Danzy Senna: Jane has high hopes that her life is about to ...

Bucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...

Danity Kane singer Dawn Richard accuses Diddy of groping her and threatening her life. She also claims to have witnessed him ...

The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.

ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...